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Abstract
Introduction: Long-lasting relapsing or lingering rheumatic musculoskeletal pain (RMSP) is the hallmark of
Chikungunya virus (CHIKV) rheumatism (CHIK-R). Little is known on their prognostic factors. The aim of this
prognostic study was to search the determinants of lingering or relapsing RMSP indicative of CHIK-R.
Methods: Three hundred and forty-six infected adults (age ≥ 15 years) having declared RMSP at disease onset
were extracted from the TELECHIK cohort study, Reunion island, and analyzed using a multinomial logistic
regression model. We also searched for the predictors of CHIKV-specific IgG titres, assessed at the time of a
serosurvey, using multiple linear regression analysis.
Results: Of these, 111 (32.1%) reported relapsing RMSP, 150 (43.3%) lingering RMSP, and 85 (24.6%) had fully
recovered (reference group) on average two years after acute infection. In the final model controlling for gender,
the determinants of relapsing RMSP were the age 45-59 years (adjusted OR: 2.9, 95% CI: 1.0, 8.6) or greater or equal
than 60 years (adjusted OR: 10.4, 95% CI: 3.5, 31.1), severe rheumatic involvement (fever, at least six joints plus four
other symptoms) at presentation (adjusted OR: 3.6, 95% CI: 1.5, 8.2), and CHIKV-specific IgG titres (adjusted OR: 3.2,
95% CI: 1.8, 5.5, per one unit increase). Prognostic factors for lingering RMSP were age 45-59 years (adjusted OR:
6.4, 95% CI: 1.8, 22.1) or greater or equal than 60 years (adjusted OR: 22.3, 95% CI: 6.3, 78.1), severe initial rheumatic
involvement (adjusted OR: 5.5, 95% CI: 2.2, 13.8) and CHIKV-specific IgG titres (adjusted OR: 6.2, 95% CI: 2.8, 13.2, per
one unit increase). CHIKV specific IgG titres were positively correlated with age, female gender and the severity of
initial rheumatic symptoms.
Conclusions: Our data support the roles of age, severity at presentation and CHIKV specific IgG titres for predicting
CHIK-R. By identifying the prognostic value of the humoral immune response of the host, this work also suggest a
significant contribution of the adaptive immune response to the physiopathology of CHIK-R and should help to
reconsider the paradigm of this chronic infection primarily shifted towards the involvement of the innate immune
response.
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Introduction
Chikungunya virus (CHIKV) is an enveloped RNA posi-
tive-strand alphavirus, transmitted by Aedes mosquitoes,
belonging to the Togaviridae family and to the arthrito-
genic Semliki forest virus (SFV) serocomplex, which
includes the well-studied Ross River virus (RRV) [1].
CHIKV is now recognised to target human epithelial and
endothelial cells, fibroblasts, dendritic cells, B cells and
macrophages [2,3], as well as human muscle satellite cells
[4].
The virus is known to cause a wide range of acute mani-
festations combining fever, arthritis, arthralgias, myalgias,
rash and fatigue [5,6]. Furthermore, CHIKV infection
often leads to prolonged joint pain, which may harbour
two different tempos; either a continuous burden or
relapse attacks that characterize the hallmark of Chikun-
gunya rheumatism (CHIK-R) [6-9]. CHIKV might also
trigger or reveal inflammatory rheumatic diseases (IRDs)
such as rheumatoid-like arthritis (RA) or psoriatic arthritis
(PsA) [10,11]. In this context, routine biomarkers (C-reac-
tive protein, CRP; erythrocyte sedimentation rate, ESR),
rheumatoid factor, anti-cyclic citrullinated peptide antibo-
dies, HLA-B27 expression, imaging features, or the need
for upgraded treatment, usually enable accurate diagnosis.
However, for the few CHIK-R patients matching the cri-
teria for IRDs, the differential diagnosis and decision-mak-
ing for treatment might be even more challenging [12-14].
Of note, the pathomechanisms underlying musculoske-
letal pain and chronic arthritide after acute CHIKV infec-
tion are partially elucidated. It has been hypothesised
that these symptoms may come from the early escape of
CHIKV from blood monocytes [3] and its subsequent
relocation and persistence in synovial macrophages
rather than to an autoimmune process [15] as previously
observed with RRV infection [16]. This hypothesis is sup-
ported by a recent macaque model in which Chikungu-
nya disease involves long-term viral persistence in
macrophages of lymphoid, liver, joint and muscle tissues
[17]. Moreover, a positive association between high titres
of CHIKV-specific IgG antibodies and long-lasting
arthralgias has been observed contemporaneously from a
pilot study by our group, and in an Italian cohort, with-
out the pathophysiological significance or clinical impact
of such relationship having been sought [18,19].
To date, the predictors of the course of CHIK-R have
so far been poorly investigated [8]. According to Sissoko
and coworkers, age over 45 years, severe initial joint
pain and underlying osteoarthritis are independent indi-
cators of non recovery [8]. These findings are consistent
with those reported in the seminal descriptions of
CHIK-R [20,21], or found in recent case series [22,23],
which showed a correlation between the age at disease
onset and the duration of rheumatic symptoms.
Recently, we conducted the TELECHIK cohort study
with the aim to address the topics of the burden of Chi-
kungunya and perceived morbidity in the community after
the 2005 to 2006 outbreak [24]. In this context, we per-
formed this ancillary study to search for prognostic factors
of long-lasting rheumatic musculoskeletal pain (RMSP)
indicative of CHIK-R. We took the opportunity of this
research to test several hypotheses with regard to a puta-
tive involvement of the host immune response in the
pathomechanism of CHIK-R. Long-lasting RMSP could be
driven by either the initial viral load or by the intensity of
viral exposure under the challenge of repeated infective
bites and waves of CHIKV in La Réunion, or by ongoing
antigenic stimulation due to the persistence of CHIKV in
host sanctuaries, using the value of CHIKV-specific IgG
antibody titre measured at plateau phase, at the time of
the seroprevalence study [25], as a proxy.
Materials and methods
Setting and design
La Réunion is a French overseas department of 787,836
inhabitants (Insee census 2006), located on a volcanic
island in the south-western part of the Indian Ocean.
During the years 2005 to 2006, 300,000 of the inhabitants
(38.2%) were considered to have been infected [25].
This study involved a subsample of the SEROCHIK and
TELECHIK studies. Both studies have been reviewed
extensively elsewhere [24,25]. The frame of the participant
selection is given in Figure 1 and Additional file 1. Sero-
prevalence estimates have been measured on average 7.6
months (range 1 to 18 months) following acute infection
for each individual, which time point was assumed to cor-
respond to the plateau phase of the production of indivi-
dual-specific-IgG and to the crucial time of evolvement to
either recovery or the chronic phase. The TELECHIK
study has been conducted in the framework of the SERO-
CHIK study between December 2007 and June 2008, on
average eighteen months after the fall of the outbreak. In
this study, the exposure to CHIKV was confirmed by
CHIKV-specific IgG ELISA antibodies [24].
Study population
The present study is a prognostic survey of the predic-
tors of CHIK-R from the TELECHIK cohort [24]. Thus,
it included all CHIKV seropositive adult participants
(age ≥ 15 years) enrolled in the TELECHIK cohort, who
had reported RMSP at disease onset.
Data collection and follow-up
Participants were interviewed by telephone. The ques-
tionnaire was administered by one investigator, blind to
the serological status, to ensure the best possible repro-
ducibility [24]. It was composed of closed questions
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addressing the course of rheumatic manifestations in
three consecutive time points (disease onset, one conco-
mitant to the SEROCHIK study, and one for the TELE-
CHIK inquiry). At disease onset, the questionnaire
aimed to define the location of joint pain (hand, wrist,
elbow, shoulder, neck, upper back, lower back, hip,
knee, ankle, foot). At the TELECHIK time point, the
questionnaire aimed to assess the clinical outcome,
which was subsequently classified as recovery, relapsing,
or lingering RMSP. Data on demographics, health status,
knowledge of CHIKV transmission, habitat and environ-
ment were gathered from the SEROCHIK study [26].
Severe initial rheumatic involvement was defined as
joint or muscle pain with fever and six or more painful
sites among those listed above, and at least four other
symptoms among the following: rash, headache, fatigue,
mood or digestive disorders. Low to moderate rheu-
matic involvement was defined as RMSP with at most
two of the preceding conditions.
Underlying comorbidities accounted for pre-existing
metabolic syndrome (MetS), rheumatic disorders, and
other chronic conditions (asthma, chronic obstructive
pulmonary disease and cancer) [24]. Rheumatic disorders
included IRDs, that is, RA, ankylosing spondylitis (AS),
PsA (axial PsA, or PsA with peripheral joint involve-
ment), hip, knee and hand osteoarthritis, and gout
[12-14]. MetS was defined by at least one of the following
conditions: body mass index ≥ 30 kg/m2, type-2 diabetes
mellitus, hypertension, or any type of dyslipidaemia. The
individual exposure level was generated by the result of a
scoring system deriving a probability of infection that
was assumed to highlight the infection load. The charac-
teristics of this scoring system of CHIKV exposure are
depicted in the footnote of Additional file 2.
The values of total CHIKV-specific IgG antibodies were
the ones provided by the SEROCHIK study. On this
behalf, the option was assumed that post-epidemic IgG
titre measured at the plateau phase might be an accurate
Figure 1 Prognostic survey participation profile. RMSP, rheumatic musculoskeletal pain. The prognostic survey cohort sample was issued
from the TELECHIK survey, a population-based cohort study (November 2007 to May 2008) (23). After elimination of 582 Chikungunya virus
(CHIKV)-seronegative subjects and 90 subjects not presenting with RMSP at disease onset, 76 subjects were excluded (50 children, 15 adults for
relocations and absence of contact, 11 for the absence of overt temporality in the clinical course of Chikungunya rheumatism), leaving 346
eligible adult participants assessed on the course of RMSP. This population was shifted towards the selection of more women and older
participants.
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proxy for the exposure level within successive immune
boosts following repeated Ae. albopictus infective bites
throughout the epidemic.
Laboratory methods
Total CHIKV-specific IgG antibodies were detected by
direct ELISA, as established at the National Reference
Centre (Pasteur Institute, Lyon, France). The technique
was automated in an ETIMax 3000® apparatus (DiaSorin,
Rome, Italy). Optical density thresholds were calculated
from a series of 30 negative sera collected in 2004, before
the epidemic [27].
Outcome measure
Recovery was defined by RMSP at disease onset, absent
at the two last follow up time points. CHIK-R was
defined by long-lasting RMSP (> 3 months), relapsing
RMSP (present at one to two time points with impossi-
bility of a conclusion of recovery), or lingering RMSP
(present at three time points), irrespective of pain and
health-related quality of life [28].
Statistical analysis
Averages of age and CHIKV-specific IgG titres were com-
pared between outcome categories using the Kruskal-
Wallis and Cuzick tests, as appropriate. Predictors of
long-lasting relapsing or lingering RMSP related to expla-
natory variables were assessed in bivariate analysis using
recovery as the referent category. Weighted cumulative
incidence rates (CIR) of RMSP were compared between
categories of predictive variables using survey-adjusted
Wald c2 tests to account for the sampling scheme (1:
probability of inclusion as sampling weight). Design-based
crude odds ratios (ORs) and 95% CI were determined for
each modality of significant variables and overall P-values
were calculated using the c2 likelihood ratio test.
At the first step of multivariate analysis, we fitted a
full multinomial logistic regression model with age, gen-
der, underlying comorbidity, exposure score, initial
rheumatic involvement and CHIKV-specific IgG titres as
explanatory variables, and relapsing or lingering RMSP
as outcome variables with recovery as the referent cate-
gory. From these covariates, we used a backward step-
wise selection procedure to drop out non significant
variables (output if P > 0.05). At the second step, we
built in a minimal multinomial logistic regression model
with all significant covariates from the precedent model
plus gender. Indeed, we decided to force the gender
because women are usually more susceptible to multiple
musculoskeletal conditions [29]. At the third step, in a
sensitivity analysis we built up a Poisson regression
model without an option for robust calculation of var-
iance, predictive of lingering RMSP with the same cov-
ariates to better assess the incidence risk ratio (IRR) of
the most pejorative outcome with recovery as reference.
Independent predictors of CHIKV-specific IgG titres
were subsequently searched using multiple linear regres-
sion analysis. Statistical significance was set at P = 0.05;
analysis was performed using Stata 10® (StataCorp.
2008, Texas, USA).
Ethical considerations
The TELECHIK study had received approval from the
ethical committee for studies with human subjects
(CPP) of Bordeaux and the National Commission for
Informatics and Liberty (CNIL), as ancillary research
completing the SEROCHIK study [24,28].
Results
Among the 422 subjects included, 50 children (age < 15
years) and 26 adults were ruled out due to fear of poorly
characterizing the course of CHIK-R, as well as to
enhance benchmarking with some of the rare articles
published in the field [6-8,18-21,30,31]. The study parti-
cipation profile is displayed in Figure 1.
Three hundred and forty-six subjects were analyzed
for the determinants of CHIK-R on average two years
after infection (range 15 to 34 months). The median age
was 50 years (range 15 to 91 years). The sex ratio of
men to women was 0.61 (131 to 215). All participants
were assessed for the CHIK-V-specific IgG value on an
average of 232 days (7.6 mo) after acute infection (range
1 to 18 mo).
The characteristics and the localizations of CHIK-R at
disease onset in this population are presented in Table 1.
In bivariate analysis, women tended to report lingering
RMSP more often than men (42.2% vs 31.9%, P = 0.083).
The intensity of the CHIK-R outcome increased with age,
from the recovery, passing through the relapsing, to the
lingering group (P < 0.001). Participants with an underly-
ing comorbidity were older than those without. Among
the latter, those with a pre-existent rheumatic disorder
were the oldest. Body mass index and previous rheumatic
disorders were not linked to CHIK-R outcome. The sub-
jects with two or more comorbidities were more likely to
declare chronic RMSP than those without an underlying
condition. The presence of MetS was associated with
both relapsing (crude OR 2.31, 95% CI 1.04, 5.12) and
lingering RMSP (crude OR 3.93, 95% CI 1.35, 8.35)
although this link was skewed by adjustment for age
(data not shown). Among the criteria defining MetS,
type-2 diabetes mellitus and dyslipidaemia were linked
irrespectively to the expression of CHIK-R, whereas
arterial hypertension was associated restrictively with lin-
gering RMSP. Renal failure was also associated with
CHIK-R outcome.
Exposure score was not related to CHIK-R, making obso-
lete the hypothesis of a relationship between recurrent
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exposures and the expression of RMSP. On the other hand,
there was a significant non linear positive association
between CHIKV-specific IgG titres and the expression of
CHIK-R. Thus, CHIKV-specific IgG level averages
increased from the recovery, passing through the relapsing,
to the lingering group (P < 0.001).
In a full multinomial logistic regression model (Table
2) controlling the exposure level, gender and underlying
comorbidities (MetS, history of IRDs and other chronic
conditions), the predictors of relapsing RMSP were age
≥ 60 years, severe initial rheumatic involvement, and
increasing CHIKV-specific IgG titres. Prognostic factors
for lingering RMSP were age ≥ 45 years (increasing OR
from the group aged 45 to 59 years group to the group
aged ≥ 60 years), severe initial rheumatic involvement
and increasing CHIKV-specific IgG titres.
The key predictors of relapsing or lingering RMSP
were identified in the minimal multinomial logistic
regression model adjusted for gender after dropping out
the exposure score and underlying comorbidities. As a
result, independent factors were age ≥ 45 years (with
increasing OR from the group aged 45 to 59 years
group to the group aged ≥ 60 years), severe initial rheu-
matic involvement and increasing CHIKV-specific IgG
titres (Table 3). Of note, the OR of the predictors of
CHIK-R increased with the intensity of CHIK-R (higher
for lingering than for relapsing RMSP). The same con-
clusion was reached taking relapsing RMSP plus recov-
ery as the reference (Additional file 3).
Interestingly, CHIKV-specific IgG titres were linked to
female gender and correlated with age but not with the
probability of infection (Table 4). The highest sex-
related difference in IgG levels was observed in the
reproductive age group (Figure 2a). Concurrently, the
highest age difference was recorded in male individuals
(Figure 2b). The CHIKV-specific IgG titre values also
correlated with the intensity of initial rheumatic involve-
ment through an age-dependent gradation that reached
significance in the oldest subjects (Figure 2c). However,
in detail, a severe clinical picture contributed to increas-
ing IgG titres only in young women (Figure 2d).
Thus, CHIKV-specific IgG titres correlated with the
intensity of CHIK-R but not to the infection load, which
argues against the notion that the rise of CHIKV-speci-
fic IgG titres may be due to re-infection following new
introduction and waves of CHIKV in La Réunion. In
another manner, the sex and age-related discrepancies
observed across the different clinical pictures at presen-
tation do not favor major involvement of the viral load
in the pathomechanism of CHIK-R. We conclude that
the host humoral response to the persistence of ongoing
antigenic stimulation is a plausible clue to long-lasting
RMSP.
Discussion
Here we report a prognostic survey of CHIK-R based on
the subset of participants reporting RMSP at the onset
of CHIKV infection, who were extracted from the TEL-
ECHIK cohort study, a population based-study aimed at
assessing the disease burden and perceived morbidity in
La Réunion island community after the 2005 to 2006
CHIKV outbreak [24]. The major findings of our survey
confirm the incidence at population level of CHIK-R
across different variable categories, and the prognostic
values of advanced age (≥ 45 years), severe initial rheu-
matic involvement at presentation, and rise in CHIKV-
specific IgG titre through the recovery/chronic phases to
predict the severity of CHIK-R over time. Thus, among
previously uninfected individuals [25], the subjects ages
45 to 59 years and particularly the oldest subjects (≥ 60
Table 1 Characteristics of 346 CHIKV-infected subjects ≥
15 years of age assessed for Chikungunya rheumatism in
the TELECHIK study, La Réunion, 2007 to 2008
Characteristics Number Unweighted*
proportion, %
Weighted**
proportion, %
Gender
Male 131 37.9 37.9
Female 215 62.1 62.1
Age
15 to 29 yrs 59 17.1 21.4
30 to 44 yrs 90 26.0 33.3
45 to 59 yrs 97 28.0 26.5
≥ 60 yrs 100 28.9 18.8
Body mass index
< 25.0 kg/m2 182 52.9 51.1
25.0 to 29.9 kg/m2 119 34.6 34.9
≥ 30.0 kg/m2 43 12.5 13.9
Sites of arthralgia at
disease onset
Hand 262 75.7 76.9
Wrist 254 73.4 74.0
Elbow 156 45.1 52.3
Shoulder 195 56.4 57.0
Neck 165 47.7 46.9
Upper back 160 46.2 45.1
Lower back 163 47.1 47.9
Hip 95 27.5 27.6
Knee 234 67.6 66.9
Ankle 259 74.9 76.3
Foot 253 73.1 73.9
Sites of arthralgia at
disease onset, n
1 21 6.1 5.3
2 to 5 118 34.1 33.8
≥ 6 207 59.8 60.0
*Percentages are calculated roughly in the subsample of the 346 analyzed
subjects; **percentages are calculated taking into account the multistage
sampling scheme.
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Table 2 Predictors of Chikungunya rheumatism issues in subjects ≥ 15 years of age (full model) in the TELECHIK study, La Réunion, 2007 to 2008
Outcomes (versus recovery as reference) Relapsing rheumatic musculoskeletal pain Lingering rheumatic musculoskeletal pain
Determinants N CIR, % Adjusted odds ratio 95% CI P- value N CIR, % Adjusted odds ratio 95% CI P- value
Gender 0.536 0.562
Male 41 34.7 1 48 31.9 1
Female 70 32.4 0.78 0.34, 1.74 102 42.2 0.78 0.33, 1.82
Age 0.013 < 0.001
15 to 29 yrs 19 27.3 1 12 20.7 1
30 to 44 yrs 32 37.9 1.60 0.57, 4.51 28 30.4 1.64 0.51, 5.31
45 to 59 yrs 27 30.0 2.67 0.78 - 9.10 52 50.2 5.62 1.52, 20.79
≥ 60 yrs 33 36.3 9.20 2.31, 36.59 58 55.6 16.03 3.82, 67.13
Underlying comorbidity 0.667 0.555
None 56 32.8 1 62 32.5 1
Metabolic syndrome without rheumatic disorders* 35 31.8 1.45 0.45, 4.65 63 53.6 1.92 0.59, 6.24
Rheumatic disorders with or without metabolic syndrome** 6 33.5 1.67 0.20, 13.53 16 53.8 2.11 0.27, 16.26
Other conditions¶ 12 44.7 2.02 0.62, 6.49 8 18.8 2.02 0.60, 6.81
Initial rheumatic involvement 0.008 0.001
Low to moderate† 70 31.8 1 77 31.0 1
Severe‡ 41 35.6 3.52 1.40, 8.87 73 50.0 5.43 1.95, 15.11
CHIKV-specific IgG titre (per one unit increase) 111 33.2 3.31 1.82, 5.99 < 0.001 150 38.3 5.72 2.74, 12.51 < 0.001
Exposure Score# 0.132 0.195
First quartile class (-2.526; -0.415) 21 32.3 1 32 38.7 1
Second quartile class (-0.400; 0.018) 27 31.9 0.60 0.20, 1.73 33 33.2 0.48 0.16, 1.42
Third quartile class (0.026; 0.432) 23 27.0 0.53 0.17, 1.70 35 41.7 0.70 0.22, 2.13
Fourth quartile class (0.433; 1.435) 25 38.3 2.09 0.57, 7.59 39 42.6 1.87 0.43, 7.97
CIR, cumulative incidence rate; CHIKV, Chikungunya virus; N, number. All estimations and P-values are weighted by the sampling scheme. *Metabolic syndrome was defined by any of the following features: body
mass index ≥ 30 kg/m2 , diabetes mellitus, arterial hypertension, or any type of dyslepidemia; **hip, knee or hand osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and psoriatic spondylarthritis and other
types of rheumatic disorders, such as gout; ¶coronary heart disease, asthma, chronic bronchitis, renal insufficiency, cancer; #exposure score build up with six covariates and two derivatives (eight components)
including residence area, housing type, a first interaction term between the residence area and housing type, deciles of altitude, household size, history of recent Chikungunya-related picture in the neighbours, a
second interaction term between the household size and history of Chikungunya, and last, the answer to the question: ‘Is Chikungunya virus a mosquito-borne virus?’. All subjects had arthralgia or muscle pain at
disease onset. †Joint or muscle pain with at most two of the three following conditions: fever, six or more localizations of arthralgia, at least four other symptoms; ‡fever and six or more localizations of arthralgia
and at least four other symptoms.
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years) were more likely to evolve towards relapsing and
lingering chronic RMSP in an age-dependant dose-
response manner. In addition, the risk estimate for
severity of CHIK-R among the individuals in the 45-59
years age group was even increased towards the cate-
gories of outcome (that is, from the relapsing to the lin-
gering feature group) in comparison with younger peers
(aged 15 to 29 years). In the same way, the subjects who
experienced severe initial rheumatic involvement (six or
more painful sites with at least four other symptoms) at
the acute stage of infection were more likely to exhibit
chronic RMSP on follow up. Concurrently, the subjects
who developed a strong CHIKV-specific IgG response
shared a similar issue. These results were robust and
were observed across different regression models con-
trolling the exposure level to the infection (that is, the
infection load) and major confounders such as female
gender and underlying comorbidities. Likewise, these
two factors have been previously recognized to be asso-
ciated with poor health-related quality of life in people
living with several musculoskeletal conditions, including
IRDs, osteoarthritis, low back pain and soft tissue disor-
ders, as reported in an Italian population [29].
It is noteworthy that in bivariate analysis female gen-
der tended to be associated with lingering RMSP. Con-
sistently, this finding has been previously reported for
persistent arthralgias among CHIKV-infected subjects
followed in the Italian cohort in the setting of the 2007
local CHIKV outbreak [19]. Of note, the strength of this
association was modulated in our cohort by the level of
the humoral immune response, which was found to be
much higher among female than male patients from
both the Réunion (P < 0.001) and Italian Chikungunya
cohorts (Figure 2a). Such a gender difference in the
CHIKV-specific IgG level was found at the baseline and
may be due to the natural estrogen-driven shift towards
the Th2 cytokine profile for promoting antibody pro-
duction in women, or to the inhibitory effect of dihydro-
testosterone (DHS) on B cell functioning in men [32].
On an other hand, it may also be due to higher produc-
tion of immunosuppressive IL-10, which has been found
to correlate positively with DHS and negatively with
serum IgG3 titres in male patients with other viral infec-
tions [33,34]. These same mechanisms may have driven
the discrepancy between IgG titres following CHIKV
infection in men and women. Interestingly, the isotypic
switch observed in Singapore CHIKV-infected patients
referred exclusively to the IgG3 subclass [35]. Though
we could not characterize the contribution of specific
IgG isoforms, our results are consistent with those of
the Italian cohort in which IL-10 levels decreased over
time following the acute stage, in parallel with the rise
in specific IgG level [36].
In the present study, more than 50% of the subjects ≥
45 years of age at the time of infection still suffered
from lingering RMSP on average two years after acute
infection (Table 2). Other contributors have found a
similar burden [6-8,22,23]. The prognostic value of
advanced age as a harbinger of CHIK-R at disease onset
has gained attention since the seminal description of
CHIK-R [20,21]. Consistently, the positive link between
age and the duration of RMSP has been confirmed in
recent years by several cohort studies [6,8,19,23]. In line
with these authors, we found a strong dose-response
between increasing age over 45 years and the severity of
CHIK-R, arguing for a causal relationship linking age to
the duration and severity of CHIK-R. Moreover, a posi-
tive association between high titres of CHIKV-specific
Table 3 Predictors of Chikungunya rheumatism issues in subjects ≥ 15 years (final model), TELECHIK study, La
Réunion, 2007-2008
Outcomes (versus recovery as reference) Relapsing rheumatic musculoskeletal pain Lingering rheumatic musculoskeletal pain
Determinants Adjusted OR 95% CI P-value Adjusted OR 95% CI P-value
Gender
Male 1 1
Female 0.92 0.44, 1.92 0.831 1.03 0.45, 2.31 0.951
Age
15 to 29 yrs 1 1
30 to 44 yrs 2.08 0.81, 5.32 0.124 2.29 0.74, 6.99 0.146
45 to 59 yrs 2.93 1.00, 8.57 0.049 6.35 1.82, 22.10 0.004
≥ 60 yrs 10.44 3.50, 31.10 < 0.001 22.30 6.36, 78.06 < 0.001
Initial rheumatic involvement
Low to moderate† 1 1
Severe‡ 3.60 1.58, 8.21 0.002 5.52 2.20, 13.81 < 0.001
CHIKV-specific IgG titre (per one unit increase) 3.16 1.82, 5.48 < 0.001 6.16 2.88, 13.20 < 0.001
OR, odds ratio; CHIKV, Chikungunya virus. All estimations and P-values are weighted by the sampling scheme. All subjects had joint or muscle pain at disease
onset. †Joint or muscle pain with at most two of the three following conditions: fever, six or more localisations of arthralgias, or at least four other symptoms;
‡fever and six or more localizations of arthralgias and at least four other symptoms.
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IgG in the plateau phase and long-lasting arthralgias has
been observed contemporaneously from a pilot study by
our group and in the Italian cohort [18,19]. A possible
mechanistic hypothesis may be that an imbalance
towards B cell expansion and differentiation, in response
to IL-6 secretion following the progression of both
immunosenescence [37] and Chikungunya [35,36,38], is
triggered by viral persistence in host sanctuaries
[15,17,18].
The contribution of underlying comorbidity has long
been considered a prerequisite to the subsequent expres-
sion of CHIK-R [5-8,18-24,31,32], and a pre-existing rheu-
matic disorder was reported among 44% of the patients
hospitalized after a CHIKV infection in La Réunion [7]. A
history of arthralgia before the outbreak was associated
with persistent joint pain in the Italian cohort [19]. Of the
rheumatic disorders that could contribute to CHIK-R, RA
[10,11,15], seronegative spondylarthritis [10,31], soft tissue
rheumatism [11], osteoarthritis [7,8], and gout [8] have
been reported to afflict CHIKV-infected patients. Pre-
viously, in the TELECHIK study, we were able to link
osteoarthritis to long-lasting RMSP in the whole cohort
[24], but failed to replicate this result in the subset of the
arthralgic participants at disease onset. Indeed, rheumatic
disorders were more likely to be associated with chronic
RMSP when associated with one or more components of
the MetS (that is, obesity, type-2 diabetes mellitus, hyper-
tension or dyslipidaemia). However, this relationship did
not resist to adjustment for age. Importantly, arterial
hypertension and cumulative comorbidities have previously
been associated with CHIK-R [8]. Therefore, a high inci-
dence of lingering RMSP was observed in MetS-positive
subjects (53.8%). On the one hand, CHIKV has been sug-
gested to trigger auto-immune IRDs such as RA or PsA
[11,12] and there is a growing body of evidence linking
IRDs to MetS [39], especially RA or PsA [40]. On the other
hand, undifferentiated arthralgias according to rheumatolo-
gic guidelines [12-14], which represent the hallmark of
CHIK-R, should be considered for specific involvement in
systemic inflammation and enhancement of MetS, assum-
ing these two risk factors are key issues in the increased
incidence of cardiovascular diseases occurring among IRD
patients [40]. The issues should be considered of impor-
tance and deserve further studies to close a putative gap
between Chikungunya and MetS.
The prognostic value of severe initial rheumatic invol-
vement for predicting long-lasting RMSP is classical
with alphaviruses, and encompasses most of the human
pathogens included in the SFV serocomplex plus the
Sindbis virus [1,41,42]. For CHIKV, it was first reported
in La Réunion [8] and subsequently confirmed in other
settings [19,22,23,30]. The intensity of symptoms at dis-
ease onset has been linked to plasma viral load, CRP
level, and Th1-driven cytokine traffic [3,15,41-44].
Indeed, in our study, a positive link between the inten-
sity of symptoms at disease onset and the course of
CHIK-R was found beyond the distribution of CHIKV-
specific IgG titre values (Tables 2 and 3, and Additional
file 3). Indeed, the relationship was found independent
of IgG levels, while observing a correlation between the
severity of the clinical picture and the IgG level (Table
4), highlighting a proper role of each of these factors on
the outcome. This relationship may involve the pivotal
action of IL-6 in the recovery phase of infection
[35,36,38], which favours the switch from innate to
adaptive immunity leading to B cell expansion and IgG3
production [35]. Although controversial, IL-6 secretion
at the acute stage may also explain the concomitant
increase in CRP level [5,43] and its predictive value for
CHIK-R [15,31].
In the absence of evidence of early-onset autoimmu-
nity or circulating immune complexes [15], the proper
role of IgG on CHIK-R remains elusive. From our study,
the fact that non-linearity characterizes the positive
association between CHIK-R and specific IgG levels
argues for the contribution of other factors. The possibi-
lity of mixed cryoglobulinemia has been suggested [45]
but not replicated in observational studies [18]. Long-
term persistence of IgM has been reported with CHIKV
[27], sometimes associated with erosive arthritis [46], so
that it is the timing of antibody commutation rather its
significance (putative persistence of CHIKV antigens)
that would be of critical importance.
Table 4 Predictors of Chikungunya virus-specific IgG
titres in subjects ≥ 15 years of age in the TELECHIK
study, La Réunion, 2007 to 2008
Full multiple regression linear model of CHIKV-specific IgG titres (n
= 309)
Variable b SD T P-value
Gender 0.143 0.088 1.63 0.105
Age, yrs 0.005 0.002 2.36 0.019
Estimated probability of infection# 0.238 0.290 0.82 0.412
Initial rheumatic involvement 0.143 0.876 1.64 0.102
Time elapsed between infection and test¶ 0.001 0.000 1.94 0.053
Constant 0.810 0.210 3.85 < 0.001
Minimal multiple regression linear model of CHIKV-specific IgG
titres (n = 344)
Variable b SD T P-value
Gender 0.183 0.081 2.25 0.025
Age, yrs 0.006 0.002 2.82 0.005
Initial rheumatic involvement 0.169 0.811 2.09 0.037
Constant 1.088 0.129 8.39 < 0.001
CHIKV, Chikungunya virus. #Derived from the exposure score; ‡fever ± six or
more localisations of arthralgias and at least four other symptoms (defined as
severe if the three conditions are gathered, low to moderate if not); ¶time
elapsed between onset of infection and ELISA test.
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We could not draw insights from the absence of a link
between the exposure level and the course of CHIK-R, or
between the infection load and CHIK-specific IgG titres.
This could be due to the fact that our exposure scoring
system did not capture the host behavior after infection
throughout the epidemic, or that of the risk of being
infected changed over time due to vector control mea-
sures. With the potential contribution of memory B cells
to the level of CHIKV-specific IgG titres and subsequent
related immunopathology, this negative finding does not
imply failure to take care to prevent the burden of CHIK-
R over the course of long-lasting CHIKV outbreaks.
Indeed, the people at risk for CHIK-R should now be tar-
geted using anti-Ae. albopictus saliva IgG abs [47].
This study has some strengths and limitations. The lim-
itations inherent in the TELECHIK study have been
reviewed extensively elsewhere [24]. Regarding the rheu-
matologic aspects of Chikungunya, one of the main
drawbacks to inference would be that in a declarative sur-
vey, patients were not examined physically by a clinician
to rule out differential diagnoses and confirm the incapa-
city. However, we had previously demonstrated that the
role of subjectivity was negligible in the TELECHIK study
[24]. Here, we have shown that the spectrum of early clini-
cal manifestations declared at disease onset are slightly
overestimated compared to those described in the setting
of medicine or rheumatology clinics [5,6]. This discre-
pancy could be explained in our study by the selection of
more female and older participants, highly susceptible to
CHIK-R, as well as by the enlargement of the window of
disease onset due to the retrospective assessment of com-
plaints, rather than to significant recall bias. Indeed, clini-
cians may also be inattentive to subtle complaints in the
context of being overwhelmed by the number of consulta-
tions during epidemics. In that case, we also demonstrate
in another sensitivity analysis that our findings are robust
Figure 2 Stratification of Chikungunya virus (CHIKV)-specific IgG titre levels according to explanatory variables in the TELECHIK study,
La Réunion, 2007 to 2008. (CHIKV)-specific IgG titre levels are shown by gender in the two age groups (A), by age in according to gender (B),
by severity of presentation in the two age groups (C), and by severity of presentation by age group and gender (D). Boxes represent medians
and interquartile (Q1-Q3) ranges, whiskers represent minimal and maximal values. Optic density values were compared using Mann-Whitney tests:
*P < 0.05; **P < 0.01; ***P < 0.001.
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and valid for the most pejorative expression of CHIK-R
(Additional file 3). Thus, we are confident that declaration
bias was unlikely to have changed the scope of our
findings.
Conclusions
The TELECHIK cohort study provides valuable clues in
the field of rheumatology by contributing to strengthen
the recognition and interpretation of the predictors of
CHIK-R. Our findings also demonstrate the putative
prognostic value of the IgG host level assessed in the
recovery/chronic phase times. Thus, the standardized
assessment of the engagement of the humoral response
and the timing of production of neutralizing IgG3 might
help to identify CHIKV patients at risk for long-lasting
RMSP. This issue might also change the paradigm from
almost exclusive interest in the innate immune response
to adaptive immune trafficking, and thus pave the way
to new avenues of research into Chikungunya [35,36].
Consistently, these perspectives should focus on an inte-
grative approach of exploring the timing of the IgG
switch and B cell signalling, innate/adaptive collabora-
tions, chronic infection and aging [37], or potential
roads to late-onset autoimmunity [48] and lymphoproli-
ferative disorders [49].
Additional material
Additional file 1: Figure showing the TELECHIK study participation
profile. The TELECHIK cohort sample was issued from the cross-sectional
SEROCHIK survey, a population-based seroprevalence study held
between 17 August and 20 October 2006, involving a random sample of
the Réunion island community (2,442 individuals), selected by the French
National Institute for Statistics and Economical studies (Insee) after
stratification by age, gender, residence area, municipality size, and
housing type [24,25]. The selection procedure of the TELECHIK
population considered six exposure strata: true positive (symptomatic
CHIKV infection), false negative (asymptomatic infection), not knowing
positive (infection without memory of symptoms and serostatus), true
negative (asymptomatic CHIKV negative to infection), false positive
(symptomatic CHIKV negative to infection), and not knowing negative
(absence of infection without memory of symptoms and serostatus), in
order to account for declaration bias and the representativeness of the
cohort, taking into account a feasibility constraint. Two subsets of the
same size of true positives and true negatives were selected after
stratification by age, gender and area of residence to control repartition
bias, the allocation of participants within the six strata being conducted
by applying reasoned sampling fractions (true positive 0.7 and true
negative 0.46), or systematic selection (false positive, not knowing
positive, false negative, not knowing negative). After elimination of those
missing the call or individuals refusing, exclusion of another 54
individuals because of incomplete data or mismatched responders
(different from the index person, parents, or legal guardian)*, the
population was slightly skewed towards the selection of more women
and older participants [23].
Additional file 2: Figure showing performances of the exposure
scoring system in predicting Chikungunya virus infection in the
development population (n = 1,863) in the SEROCHIK study, 2006.
The exposure score was built up with six covariates and two derivatives
(eight components) including residence area (north, west, south, east),
housing type (collective/individual), a first interaction term between
residence area and housing type, deciles of altitude, household size (1, 2
to 4, ≥ 5 persons), history of recent Chikungunya-related picture in the
neighbours (no/yes/don’t know), a second interaction term between the
household size and history of Chikungunya, and last, the answer to the
question: ‘Is Chikungunya virus a mosquito-borne virus (no/yes)?’. It was
developed from a population of 2,101 eligible adult individuals (≥ 15
years of age) enrolled in the SEROCHIK survey. After elimination of 238
individuals (11.3%) due to missing data, the score displayed a range of
320 eigen values in 1,863 individuals according to a continuous
multimodal distribution. The discrimination (or the ability to distinguish
infected from uninfected individuals) and calibration (or the adequation
between predicted and observed infections over a range of probabilities)
performances of the exposure scoring system were considered both
satisfactory in the development population (receiver operator
characteristic area or Az index: 0.70, 95% CI 0.67, 0.72; goodness of fit F-
adjusted test, P = 0.840).
Additional file 3: Table showing sensitivity analysis predicting
lingering rheumatic musculoskeletal pain in subjects ≥ 15 years of
age in a Poisson regression model in the TELECHIK survey, La
Réunion, 2007 to 2008.
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